These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22495373)

  • 1. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score.
    Zbytek B; Cohen C; Wang J; Page A; Williams DJ; Adams AL
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):48-53. PubMed ID: 22495373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.
    Williams DJ; Cohen C; Darrow M; Page AJ; Chastain B; Adams AL
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):431-6. PubMed ID: 21297447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies.
    Puripat N; Loharamtaweethong K
    Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
    Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
    Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.
    Chang JM; McCullough AE; Dueck AC; Kosiorek HE; Ocal IT; Lidner TK; Gray RJ; Wasif N; Northfelt DW; Anderson KS; Pockaj BA
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S509-15. PubMed ID: 26001860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J; Kim M; Fineberg S
    Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of mitosis counting by automated phosphohistone H3 (PHH3) digital image analysis in a breast carcinoma tissue microarray.
    Dessauvagie BF; Thomas C; Robinson C; Frost FA; Harvey J; Sterrett GF
    Pathology; 2015 Jun; 47(4):329-34. PubMed ID: 25938351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
    Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation oncotype DX
    Lashen A; Toss MS; Fadhil W; Oni G; Madhusudan S; Rakha E
    Histopathology; 2023 Apr; 82(5):755-766. PubMed ID: 36631400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
    Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
    Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotic index matter: how to improve the assessment of mitosis in order to better classify G2 breast cancer and luminal A category.
    Del Sordo R; Bellezza G; Ferri I; Pireddu A; Colella R; Sidoni A
    Histol Histopathol; 2018 Jan; 33(1):81-88. PubMed ID: 28332699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
    Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
    PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
    Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
    Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
    Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
    J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer.
    Lee LH; Swanson PE; Tang PA; Bigras G; Yang H
    Appl Immunohistochem Mol Morphol; 2017 Jan; 25(1):25-31. PubMed ID: 26371428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
    Allison KH; Kandalaft PL; Sitlani CM; Dintzis SM; Gown AM
    Breast Cancer Res Treat; 2012 Jan; 131(2):413-24. PubMed ID: 21369717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
    Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P
    Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.